Skip to main content

A new algorithm identifies the patients that will most benefit from immunotherapy

25 Nov 19




Press and Communications Officer
Tel.+34 93 40 37255

RTVE, the newspaper Heraldo de Aragón, and Diario Médico—the newspaper specialized in health—among other media, have echoed on a new algorithm, developed by researchers at IRB Barcelona in collaboration with the Centre for Genomic Regulation and the University of Radboud, that allows identification of those patients who are most likely to benefit from immunotherapy. Based on machine learning, the scientists have developed a tool that detects the genetic mutations that activate the immune system. This algorithm also identifies those people with certain hereditary diseases that would benefit from certain kinds of drug already on the market. The study was published in the journal Nature Genetics.



Link to RTVE 

Link to Heraldo de Aragón 

Link to Diario Médico

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).